The target index of the Penghua Hong Kong-Stock Connect Pharma ETF (513700) rose by more than 1.5%, the target index of the Penghua Hang Seng Biotech ETF (159130) rose by more than 1.7%, and WuXi He althcare’s interim profit increased 37.4% year-on-year

On the news front, on August 24, WuXi He althcare (Wuxi United?) released its 2026 interim results. The financial report shows that in the first half of 2026, WuXi He althcare generated comprehensive income of RMB 3.701 billion. Based on the actual exchange rate (AER), this represents a year-on-year increase of 37.0%; based on the constant exchange rate (CER), the year-on-year increase is 41.5%. Gross profit grew 40.6% year-on-year to RMB 1.371 billion, and gross margin further improved to 37.0%. Adjusted net profit attributable to the parent company increased 37.4% year-on-year to RMB 1.027 billion, and adjusted net profit margin remained stable at 27.8%.
In its analysis, Everbright Securities notes that China’s innovative drug companies are gradually shifting from a “guerrilla warfare” model that relies on License-out toward a “base” model that builds a closed-loop of local value through Co-Co (co-development) and NewCo (newly established companies). BeiGene has delivered full-year profitability thanks to global rights to zanubrutinib. Meanwhile, Innovent Biologics’ collaboration with BMS preserves global commercialization choice. These developments indicate that leading companies are starting to systematically keep intellectual property and the associated revenue mechanisms within domestic entities. This shift not only reshapes how capital markets value innovative drug firms, but also drives more sustainable demand growth for upstream industries such as CXO and research reagents.
As of 09:55 on August 25, 2026, the underlying index of Hang Seng China Enterprises Medical Health ETF (Penghua) (513700)—the China Securities Index of Hang Seng Stock Connect Medical and Health Services (930965)—rose strongly by 1.55%. Among the constituent stocks, WuXi Healian rose 9.60%, Xtal?tech rose 6.73%, GenScript? Biotech rose 5.89%, Rongchang Biotech, and other stocks such as Vist? Yunding? New? Hon? also followed higher. The underlying index of the Hang Seng Biomedical Technology ETF (Penghua) (159130)—the Hang Seng Biomedical Technology Index (HSBIO)—rose strongly by 1.72%.
The Hang Seng China Enterprises Medical Health ETF (Penghua) tracks the China Securities Index of Hang Seng Stock Connect Medical and Health Services. The index selects 50 medical and healthcare sector listed companies within the Stock Connect of Hong Kong stocks that have good liquidity and large market capitalizations as index constituents, to reflect the overall performance of medical and healthcare securities within the Stock Connect of Hong Kong stocks.
Data shows that as of July 31, 2026, the top 10 weighted stocks of the China Securities Index of Hang Seng Stock Connect Medical and Health Services (930965) are WuXi Biologics, BeiGene, Innovent Biologics, WuXi AppTec, CanSino? Biosciences, CSPC Group, Hansoh Pharmaceutical, China Biopharmaceutical, JD Health, and Sansheng Pharmaceutical. The combined share of the top 10 weighted stocks is 65.69%.
Hang Seng China Enterprises Medical Health ETF (Penghua) (513700), off-exchange connection (A: 021088; C: 021089; I: 022844).